company background image
HRMY

Harmony Biosciences HoldingsNasdaqGM:HRMY Stock Report

Market Cap

US$2.1b

7D

3.9%

1Y

18.7%

Updated

23 Sep, 2021

Data

Company Financials +
HRMY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health3/6
Dividends0/6

HRMY Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders.

Harmony Biosciences Holdings Competitors

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$7.9b

Price History & Performance

Summary of all time highs, changes and price drops for Harmony Biosciences Holdings
Historical stock prices
Current Share PriceUS$38.54
52 Week HighUS$25.09
52 Week LowUS$52.74
Beta0
1 Month Change16.33%
3 Month Change30.29%
1 Year Change18.69%
3 Year Changen/a
5 Year Changen/a
Change since IPO4.13%

Recent News & Updates

Aug 17
Harmony Biosciences Holdings' (NASDAQ:HRMY) Promising Earnings May Rest On Soft Foundations

Harmony Biosciences Holdings' (NASDAQ:HRMY) Promising Earnings May Rest On Soft Foundations

Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) just reported some strong earnings, and the market rewarded them...

Shareholder Returns

HRMYUS PharmaceuticalsUS Market
7D3.9%0.2%-0.5%
1Y18.7%15.5%37.5%

Return vs Industry: HRMY exceeded the US Pharmaceuticals industry which returned 13.8% over the past year.

Return vs Market: HRMY underperformed the US Market which returned 36.2% over the past year.

Price Volatility

Is HRMY's price volatile compared to industry and market?
HRMY volatility
HRMY Beta0
Industry Beta0.64
Market Beta1

Stable Share Price: HRMY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: HRMY's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017150John Jacobshttps://www.harmonybiosciences.com

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.

Harmony Biosciences Holdings Fundamentals Summary

How do Harmony Biosciences Holdings's earnings and revenue compare to its market cap?
HRMY fundamental statistics
Market CapUS$2.14b
Earnings (TTM)US$17.19m
Revenue (TTM)US$235.39m

127.8x

P/E Ratio

9.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HRMY income statement (TTM)
RevenueUS$235.39m
Cost of RevenueUS$40.91m
Gross ProfitUS$194.49m
ExpensesUS$177.29m
EarningsUS$17.19m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.34
Gross Margin82.62%
Net Profit Margin7.30%
Debt/Equity Ratio154.6%

How did HRMY perform over the long term?

See historical performance and comparison

Valuation

Is Harmony Biosciences Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HRMY ($38.54) is trading below our estimate of fair value ($248.69)

Significantly Below Fair Value: HRMY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HRMY is poor value based on its PE Ratio (127.8x) compared to the US Pharmaceuticals industry average (22x).

PE vs Market: HRMY is poor value based on its PE Ratio (127.8x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

PEG Ratio: HRMY is poor value based on its PEG Ratio (2.9x)


Price to Book Ratio

PB vs Industry: HRMY is overvalued based on its PB Ratio (17.4x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Harmony Biosciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

44.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HRMY's forecast earnings growth (44.1% per year) is above the savings rate (2%).

Earnings vs Market: HRMY's earnings (44.1% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HRMY's revenue (30.8% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: HRMY's revenue (30.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HRMY's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Harmony Biosciences Holdings performed over the past 5 years?

268.7%

Last years revenue growth


Earnings and Revenue History

Quality Earnings: HRMY has a high level of non-cash earnings.

Growing Profit Margin: HRMY became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: HRMY has become profitable over the past 5 years.

Accelerating Growth: HRMY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: HRMY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: HRMY's Return on Equity (18.3%) is considered low.


Financial Health

How is Harmony Biosciences Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: HRMY's short term assets ($204.7M) exceed its short term liabilities ($36.6M).

Long Term Liabilities: HRMY's short term assets ($204.7M) exceed its long term liabilities ($196.5M).


Debt to Equity History and Analysis

Debt Level: HRMY's debt to equity ratio (154.6%) is considered high.

Reducing Debt: Insufficient data to determine if HRMY's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: HRMY's debt is well covered by operating cash flow (25.3%).

Interest Coverage: HRMY's interest payments on its debt are not well covered by EBIT (1.9x coverage).


Balance Sheet


Dividend

What is Harmony Biosciences Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HRMY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HRMY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HRMY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HRMY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HRMY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

John Jacobs (53 yo)

3.25yrs

Tenure

US$3,230,374

Compensation

Mr. John Charles Jacobs, MBA, serves as President and Chief Executive Officer of Harmony Biosciences, LLC. He serves as Director at Life Sciences Pennsylvania since May 6, 2021. He served as Chairman of Ha...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD3.23M) is about average for companies of similar size in the US market ($USD3.68M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: HRMY's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: HRMY's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 635.5%.


Top Shareholders

Company Information

Harmony Biosciences Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Harmony Biosciences Holdings, Inc.
  • Ticker: HRMY
  • Exchange: NasdaqGM
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.136b
  • Shares outstanding: 57.01m
  • Website: https://www.harmonybiosciences.com

Number of Employees


Location

  • Harmony Biosciences Holdings, Inc.
  • 630 West Germantown Pike
  • Suite 215
  • Plymouth Meeting
  • Pennsylvania
  • 19462
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 23:09
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.